Title 13. Miscellaneous Health Care Programs — Subtitle 35. Co-Prescribing of Opioid Overdose Reversal Drugs
Statutes in effect as of October 1, 2026.
Md. Code Ann., Health-Gen. § 13-3501 (2026)
Title 13. Miscellaneous Health Care Programs
Subtitle 35. Co-Prescribing of Opioid Overdose Reversal Drugs
§ 13–3501LinkCopy Citation
(a)
In this subtitle the following words have the meanings indicated.
(b)
“Co–prescribing” means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at an elevated risk of overdose.
(c)
“Opioid overdose reversal drug” means naloxone or a similarly acting and equally safe drug that is approved by the federal Food and Drug Administration for the treatment of a known or suspected opioid overdose.
Md. Code Ann., Health-Gen. § 13-3502 (2026)
Title 13. Miscellaneous Health Care Programs
Subtitle 35. Co-Prescribing of Opioid Overdose Reversal Drugs
§ 13–3502LinkCopy Citation
(a)
The Secretary shall establish guidelines for the co–prescribing of opioid overdose reversal drugs that are applicable to all licensed health care providers in the State who are authorized by law to prescribe a monitored prescription drug, as defined in § 21–2A–01 of this article.
(b)
The guidelines established under subsection (a) of this section shall address the co–prescribing of opioid overdose reversal drugs for patients who are:
(1)
At an elevated risk of overdose; and
(2)
(i)
Receiving opioid therapy for chronic pain;
(ii)
Receiving a prescription for benzodiazepines; or
(iii)
Being treated for opioid use disorders.